Wolfe Research on Ionis Pharmaceuticals (IONS): new Tryngolza pricing likely to ‘squeeze’ Arrowhead’s rival drug

March 25, 2026 9:46 AM

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $97.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found